Mechanisms of therapeutic CDK4/6 inhibition in breast cancer

2017 Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al (eds). SEER cancer statistics review, 1975-2014. Bethesda, MD; National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/. Kohler, 2015, Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state, J Natl Cancer Inst, 107, djv048, 10.1093/jnci/djv048 Altundag, 2006, Aromatase inhibitors in breast cancer: an overview, Oncologist, 11, 553, 10.1634/theoncologist.11-6-553 Onitilo, 2009, Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival, Clin Med Res, 7, 4, 10.3121/cmr.2008.825 Polk, 2016, Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence, ESMO Open, 1, e000093, 10.1136/esmoopen-2016-000093 Cordon-Cardo, 1995, Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia, Am J Pathol, 147, 545 Malumbres, 2005, Mammalian cyclin-dependent kinases, Trends Biochem Sci, 30, 630, 10.1016/j.tibs.2005.09.005 Nurse, 1997, Regulation of the eukaryotic cell cycle, Eur J Cancer, 33, 1002, 10.1016/S0959-8049(97)00091-9 Bloom, 2007, Multiple levels of cyclin specificity in cell-cycle control, Nat Rev Mol Cell Biol, 8, 149, 10.1038/nrm2105 Sherr, 1996, Cancer cell cycles, Science, 274, 1672, 10.1126/science.274.5293.1672 Markey, 2007, Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function, Oncogene, 26, 6307, 10.1038/sj.onc.1210450 Sherr, 1994, G1 phase progression: cycling on cue, Cell, 79, 551, 10.1016/0092-8674(94)90540-1 Medema, 1995, Growth suppression by p16ink4 requires functional retinoblastoma protein, Proc Natl Acad Sci U S A, 92, 6289, 10.1073/pnas.92.14.6289 Finn, 2016, Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers, Breast Cancer Res, 18, 17, 10.1186/s13058-015-0661-5 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, 9, 153, 10.1038/nrc2602 Wang, 1994, Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice, Nature, 369, 669, 10.1038/369669a0 Musgrove, 1994, Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle, Proc Natl Acad Sci U S A, 91, 8022, 10.1073/pnas.91.17.8022 Yu, 2001, Specific protection against breast cancers by cyclin D1 ablation, Nature, 411, 1017, 10.1038/35082500 Rane, 2002, Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence, Mol Cell Biol, 22, 644, 10.1128/MCB.22.2.644-656.2002 Bowe, 2002, Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E, Oncogene, 21, 291, 10.1038/sj.onc.1205025 Reddy, 2005, Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis, Cancer Res, 65, 10174, 10.1158/0008-5472.CAN-05-2639 Yu, 2006, Requirement for CDK4 kinase function in breast cancer, Cancer Cell, 9, 23, 10.1016/j.ccr.2005.12.012 Landis, 2006, Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis, Cancer Cell, 9, 13, 10.1016/j.ccr.2005.12.019 Choi, 2012, The requirement for cyclin D function in tumor maintenance, Cancer Cell, 22, 438, 10.1016/j.ccr.2012.09.015 Fantl, 1990, Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer, Eur J Cancer, 26, 423, 10.1016/0277-5379(90)90009-I Buckley, 1993, Expression and amplification of cyclin genes in human breast cancer, Oncogene, 8, 2127 Gillett, 1994, Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining, Cancer Res, 54, 1812 Bartkova, 1994, Cyclin D1 protein expression and function in human breast cancer, Int J Cancer, 57, 353, 10.1002/ijc.2910570311 Weinstat-Saslow, 1995, Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions, Nat Med, 1, 1257, 10.1038/nm1295-1257 Zukerberg, 1995, Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene, Mod Pathol, 8, 560 An, 1999, Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation, Am J Pathol, 154, 113, 10.1016/S0002-9440(10)65257-1 Trere, 2009, High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy, Ann Oncol, 20, 1818, 10.1093/annonc/mdp209 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Bosco, 2007, RB in breast cancer: at the crossroads of tumorigenesis and treatment, Cell Cycle, 6, 667, 10.4161/cc.6.6.3988 Voduc, 2008, The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype, Hum Pathol, 39, 1431, 10.1016/j.humpath.2008.03.004 Witkiewicz, 2014, CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models, Genes Cancer, 5, 261, 10.18632/genesandcancer.24 Garrido-Castro, 2017, CDK4/6 inhibition in breast cancer: mechanisms of response and treatment failure, Curr Breast Cancer Rep, 9, 26, 10.1007/s12609-017-0232-0 Sherr, 1999, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev, 13, 1501, 10.1101/gad.13.12.1501 Foster, 1996, Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells, Mol Endocrinol, 10, 488 Altucci, 1996, 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells, Oncogene, 12, 2315 Lukas, 1996, Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint, Mol Cell Biol, 16, 6917, 10.1128/MCB.16.12.6917 Said, 1997, Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo, Endocrinology, 138, 3933, 10.1210/endo.138.9.5436 Zwijsen, 1997, CDK-independent activation of estrogen receptor by cyclin D1, Cell, 88, 405, 10.1016/S0092-8674(00)81879-6 Neuman, 1997, Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4, Mol Cell Biol, 17, 5338, 10.1128/MCB.17.9.5338 Lenferink, 2001, ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways, Cancer Res, 61, 6583 Kilker, 2006, Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells, Cancer Res, 66, 11478, 10.1158/0008-5472.CAN-06-1755 Bosco, 2007, The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer, J Clin Invest, 117, 218, 10.1172/JCI28803 Butt, 2005, Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E, Endocr Relat Cancer, 12, S47, 10.1677/erc.1.00993 Ahlin, 2017, High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers, Breast Cancer Res Treat, 164, 667, 10.1007/s10549-017-4294-5 Toogood, 2005, Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6, J Med Chem, 48, 2388, 10.1021/jm049354h Carlson, 1996, Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells, Cancer Res, 56, 2973 Sedlacek, 1996, Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy, Int J Oncol, 9, 1143 Carlson, 1999, Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol, Cancer Res, 59, 4634 Li, 2000, Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol, Clin Cancer Res, 6, 223 Wu, 2002, Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways, Mol Cancer Ther, 1, 695 Mgbonyebi, 1999, Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells, Cancer Res, 59, 1903 Goodyear, 2007, Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5, Exp Mol Pathol, 82, 25, 10.1016/j.yexmp.2006.09.002 Nair, 2011, Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells, Breast Cancer Res, 13, R80, 10.1186/bcr2929 Parry, 2010, Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor, Mol Cancer Ther, 9, 2344, 10.1158/1535-7163.MCT-10-0324 Sun, 2011, Effects of an Indolocarbazole-Derived CDK4 Inhibitor on breast cancer cells, J Cancer, 2, 36, 10.7150/jca.2.36 Fornier, 2007, Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors, Clin Cancer Res, 13, 5841, 10.1158/1078-0432.CCR-07-1218 Le Tourneau, 2010, Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies, Eur J Cancer, 46, 3243, 10.1016/j.ejca.2010.08.001 Fry, 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol Cancer Ther, 3, 1427, 10.1158/1535-7163.1427.3.11 Finn, 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, 11, R77, 10.1186/bcr2419 Roberts, 2012, Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, 104, 476, 10.1093/jnci/djs002 Dean, 2012, Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors, Cell Cycle, 11, 2756, 10.4161/cc.21195 Kim, 2013, LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6–reactivating Rb in cancer, Mol Cancer Ther, 12, 10.1158/1535-7163.TARG-13-PR02 O'Brien, 2014, In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer, Cancer Res, 74 Gelbert, 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest New Drugs, 32, 825, 10.1007/s10637-014-0120-7 Torres-Guzman, 2017, Preclinical characterization of abemaciclib in hormone receptor positive breast cancer, Oncotarget, 8, 69493, 10.18632/oncotarget.17778 Marzec, 2006, Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity, Blood, 108, 1744, 10.1182/blood-2006-04-016634 Baughn, 2006, A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6, Cancer Res, 66, 7661, 10.1158/0008-5472.CAN-06-1098 Menu, 2008, A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model, Cancer Res, 68, 5519, 10.1158/0008-5472.CAN-07-6404 Goel, 2016, Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors, Cancer Cell, 29, 255, 10.1016/j.ccell.2016.02.006 Tate, 2014, Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts, Clin Cancer Res, 20, 3763, 10.1158/1078-0432.CCR-13-2846 Raub, 2015, Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft, Drug Metab Dispos, 43, 1360, 10.1124/dmd.114.062745 Patnaik, 2016, Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors, Cancer Discov, 6, 740, 10.1158/2159-8290.CD-16-0095 Joshi, 2007, In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00, Mol Cancer Ther, 6, 918, 10.1158/1535-7163.MCT-06-0613 Horiuchi, 2012, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, J Exp Med, 209, 679, 10.1084/jem.20111512 Mita, 2014, Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer, Clin Breast Cancer, 14, 169, 10.1016/j.clbc.2013.10.016 Mitri, 2015, A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer, Invest New Drugs, 33, 890, 10.1007/s10637-015-0244-4 Dey, 2016, 76, 2835 Gupta, 2012, A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors, J Clin Oncol, 30, 3011, 10.1200/jco.2012.30.15_suppl.3011 Bisi, 2017, Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors, Oncotarget, 8, 42343, 10.18632/oncotarget.16216 Wang, 2017, CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest, J Transl Med, 15, 127, 10.1186/s12967-017-1231-7 Hu, 2016, Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies, Clin Cancer Res, 22, 2000, 10.1158/1078-0432.CCR-15-1421 Finn, 2016, Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18, Breast Cancer Res, 18, 67, 10.1186/s13058-016-0721-5 Spring, 2017, Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations, Oncologist, 22, 1039, 10.1634/theoncologist.2017-0142